Related Substances Analysis of Traditional Chinese Medicine: Methods, Standards, and Applications

Related substances analysis of Traditional Chinese Medicine (TCM) is a critical quality control discipline that identifies, quantifies, and controls impurities in herbal materials, extracts, and finished formulations throughout their lifecycle. Because TCM products are complex multi-component systems, modern analytical platforms such as HPLC, UHPLC, and LC-MS/MS are essential for detecting degradation products, process-related impurities, and inherently toxic constituents. This article provides a comprehensive technical overview of related substances analysis in TCM, covering sample types, testing items, validated analytical methods, regulatory applications, and frequently asked questions.

Technical Overview

Related substances, also referred to as impurities, are chemical entities present in a pharmaceutical product other than the declared active ingredients and excipients. In the context of Traditional Chinese Medicine (TCM), related substances analysis encompasses the detection, identification, quantification, and control of degradation products, residual toxic natural constituents, extraction and processing impurities, and contaminants introduced during manufacturing, packaging, or storage.

Unlike synthetic small-molecule drugs, TCM products are inherently complex systems containing hundreds of structurally diverse compounds, including alkaloids, glycosides, flavonoids, terpenoids, tannins, and volatile oils. This chemical complexity makes impurity profiling substantially more challenging: degradation products may co-elute with active markers, unknown peaks may be difficult to assign, and the toxicological significance of trace components may not be fully characterized. Consequently, a risk-based, science-driven approach is required.

Regulatory expectations for related substances control in TCM are articulated in the Chinese Pharmacopoeia (ChP) general requirements, technical guidelines issued by the National Medical Products Administration (NMPA), and principles adapted from ICH Q3A and Q3B, which are modified to account for the multi-component nature of botanical products. Increasingly, special attention is directed toward inherently hazardous constituents such as aristolochic acids, pyrrolizidine alkaloids, aconitine-type diterpenoid alkaloids, and mycotoxins, for which stringent limits are enforced regardless of their origin.

A scientifically sound related substances strategy for TCM typically integrates the following elements: characterization of the chemical profile of the herbal material and formulation, identification of potential impurity sources, development of stability-indicating analytical methods, toxicological qualification of impurities, and establishment of justified acceptance criteria with appropriate control points in the manufacturing process.

Testing Samples

Raw Herbal Materials and Decoction Pieces

Crude herbal materials and processed decoction pieces represent the starting point of the impurity control chain. Testing at this stage focuses on intrinsic toxic constituents, adulterants and substitution species, degradation of marker compounds during drying and storage, and contamination introduced during cultivation, harvesting, or post-harvest handling. Because impurities in raw materials propagate downstream, early-stage screening is a cost-effective control strategy.

Extracts and Manufacturing Intermediates

Concentrated extracts, fractions, and intermediates generated during extraction, purification, and concentration steps are analyzed to track process-related impurities. These may include extraction solvent residues, transformation products formed under heated or acidic/basic processing conditions, and carryover of undesirable co-extracted components. Intermediate testing helps establish hold-time limits and confirm the effectiveness of purification unit operations.

Finished Dosage Forms

Finished TCM products, including tablets, capsules, granules, pills, oral liquids, tinctures, and topical preparations, are subject to release and stability testing for related substances. The dosage form matrix, including excipients and coating materials, must be considered during method development to ensure that formulation components do not interfere with impurity detection.

TCM Injections

Injectable TCM preparations are subject to the most stringent impurity control requirements due to the elevated safety risk associated with parenteral administration. Related substances testing for TCM injections typically requires comprehensive impurity profiling, individual and total impurity limits, mass balance assessment, and structural elucidation of significant unknown impurities, often supported by high-resolution mass spectrometry.

Testing Items

Related substances testing programs for TCM products typically include the following categories of test items:

• Degradation products: Impurities formed through hydrolysis, oxidation, photolysis, isomerization, polymerization, or thermolysis of active or marker constituents during manufacturing and storage.
• Inherently toxic natural constituents: Regulated hazardous components such as aristolochic acid I and II, pyrrolizidine alkaloids, aconitine and its hydrolysis products, strychnine, and scopolamine-type alkaloids, which require strict limit testing.
• Process-related impurities: Residual reagents, extraction aids, purification by-products, and carryover from upstream steps such as alcohol precipitation or resin-based separation.
• Contaminants of related concern: Mycotoxins including aflatoxins B1, B2, G1, and G2, ochratoxin A, and zearalenone, which arise from fungal contamination of herbal materials.
• Individual specified impurities: Known, structurally characterized impurities with individually established acceptance limits.
• Unspecified impurities: Any other detectable impurity peaks, controlled by a general reporting or identification threshold.
• Total impurities: The sum of all impurity peak responses, controlled by an overall acceptance criterion.

Testing Methods

Method selection for related substances analysis depends on the chemical nature of the expected impurities, the complexity of the matrix, and the required sensitivity. A combination of orthogonal techniques is frequently employed to ensure comprehensive coverage.

Reversed-Phase HPLC with UV/DAD Detection

Reversed-phase high-performance liquid chromatography coupled with ultraviolet or diode-array detection remains the workhorse technique for TCM related substances testing. Diode-array detection provides spectral information that aids peak purity assessment and preliminary characterization of unknown impurities. Gradient elution with acidified water and acetonitrile or methanol mobile phases is commonly used to resolve the wide polarity range of herbal components.

UHPLC and High-Resolution Separations

Ultra-high-performance liquid chromatography employing sub-2-micron particle columns delivers superior resolution, sensitivity, and throughput. This is particularly valuable for complex TCM matrices where impurity peaks may otherwise co-elute with abundant matrix components, and it enables reliable integration of trace-level impurities in shorter run times.

LC-MS/MS and High-Resolution Mass Spectrometry

Mass spectrometric detection is indispensable for impurity identification, structural elucidation, and trace-level quantification of highly toxic constituents. Triple quadrupole LC-MS/MS operated in multiple reaction monitoring mode achieves parts-per-billion sensitivity for regulated toxins such as aristolochic acid and pyrrolizidine alkaloids, while high-resolution accurate-mass spectrometry supports the identification of unknown degradation products through accurate mass measurement and fragmentation pathway analysis.

GC and GC-MS for Volatile Impurities

Gas chromatography is applied to volatile-related substances, including degraded components of volatile oils, residual extraction solvents, and certain volatile toxic constituents. Headspace GC-MS sampling minimizes matrix interference and is well suited for residual solvent profiling.

Universal and Complementary Detectors

For impurities lacking UV chromophores, evaporative light-scattering detection (ELSD), charged aerosol detection (CAD), or refractive index detection may be incorporated. These detectors provide near-universal response and improve mass-balance assessment, although quantification typically requires reference standards or response factor correction.

Forced Degradation Studies

Stability-indicating capability is demonstrated through forced degradation studies in which samples are stressed under acid and base hydrolysis, oxidative conditions, thermal stress, photolysis, and humidity. The resulting degradation profiles confirm that the analytical method can resolve degradation products from active components and validate the method's specificity for stability testing.

Method Validation Parameters

Validated related substances methods must demonstrate performance across the following attributes, consistent with ICH Q2(R2) and pharmacopoeial requirements:

• Specificity and peak purity, including resolution from adjacent matrix peaks
• Linearity and range covering reporting threshold to above the specification limit
• Accuracy, assessed by recovery studies at impurity spike levels
• Precision, including repeatability and intermediate precision
• Limit of detection and limit of quantification for each monitored impurity
• Robustness against deliberate variations in method parameters
• Solution stability of sample and standard preparations

Quantification Strategies

Quantification is preferably performed against impurity reference standards. Where standards are unavailable, dilution-to-standardization using the principal component standard with relative response factors, or peak area percentage approaches, may be justified, provided that response differences between the standard and impurities are characterized and appropriately corrected.

Applications

Related substances analysis serves multiple functions across the TCM product lifecycle:

• Quality control and batch release: Confirming that each manufactured batch meets established individual and total impurity limits prior to distribution.
• Stability studies and shelf-life determination: Supporting long-term and accelerated stability programs under ICH Q1A conditions to establish retest periods and expiration dating.
• Process development and optimization: Identifying impurity formation mechanisms and verifying that extraction, purification, and concentration steps reduce impurity levels to target ranges.
• Regulatory submissions: Providing impurity profiling data for investigational new drug applications, marketing authorization dossiers, and pharmacopoeial monograph development.
• Safety assessment and risk qualification: Establishing toxicological justification for impurity limits, particularly for genotoxic or highly potent natural constituents.
• Post-marketing surveillance: Monitoring commercial product quality, investigating adverse event reports, and verifying supply chain integrity.
• Herbal material authentication: Detecting adulteration, species substitution, and contamination at the raw material stage before downstream manufacturing.

FAQ

What are related substances in Traditional Chinese Medicine?

Related substances in TCM are any components other than the intended active or marker constituents, including degradation products, inherently toxic natural compounds, process-related impurities, and contaminants such as mycotoxins. Their control is essential for ensuring product safety, efficacy, and batch-to-batch consistency.

Why is related substances analysis more difficult for TCM than for synthetic drugs?

TCM products contain large numbers of structurally diverse compounds, which creates dense chromatograms, increases the risk of co-elution, and complicates the assignment and toxicological qualification of unknown peaks. Multi-component methods with high resolving power and mass spectrometric support are typically required.

Which analytical technique is most appropriate for TCM impurity testing?

Reversed-phase HPLC with diode-array detection is the standard starting point for routine control, while UHPLC improves resolution and throughput. LC-MS/MS and high-resolution mass spectrometry are essential for impurity identification and for trace-level quantification of regulated toxic constituents. The optimal approach often combines multiple orthogonal techniques.

Are forced degradation studies required for TCM products?

Yes. Forced degradation studies under acid, base, oxidative, thermal, photolytic, and humidity stress conditions are required to demonstrate that the analytical method is stability-indicating and to understand the degradation pathways of key constituents, particularly for registration stability submissions.

How are unknown impurities handled when reference standards are unavailable?

Unknown impurities are initially controlled using reporting and identification thresholds based on daily intake and toxicological principles. When a threshold is exceeded, the impurity should be isolated and structurally characterized, typically by high-resolution mass spectrometry and NMR, and subsequently qualified toxicologically or controlled through process modification.

What limits apply to toxic constituents such as aristolochic acids?

Regulated toxic constituents are subject to stringent pharmacopoeial limits, often at trace levels requiring LC-MS/MS sensitivity. Manufacturers must implement sourcing controls, species authentication, and validated limit tests to ensure compliance throughout the supply chain.